Prevalence and Clinical Impact of Respiratory Viral Infections from the STOP2 Study of Cystic Fibrosis Pulmonary Exacerbations
Christina S. Thornton(University of Calgary), John J. LiPuma(University of Michigan), Natalie E. West(Johns Hopkins University), Patrick A. Flume(Medical University of South Carolina), William LeBar(University of Michigan), Lisa A. Carmody(University of Michigan), Scott McClellan(University of Michigan), Donald R. VanDevanter(Case Western Reserve University), Lindsay J. Caverly(University of Michigan), Christopher H. Goss(University of Washington Medical Center), Linda M. Kalikin(University of Michigan), Sonya L. Heltshe, Don B. Sanders(Indiana University School of Medicine)
Cited by 20
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections
|American Journal of Respiratory and Critical Care Medicine|2017|393
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by <i>Mycobacterium avium</i> Complex (CONVERT). A Prospective, Open-Label, Randomized Study
|American Journal of Respiratory and Critical Care Medicine|2018|343
Taxon K, a complex within the Burkholderia cepacia complex, comprises at least two novel species, Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov.
|INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY|2009|317
Pulmonary complications after esophagectomy
|The Annals of Thoracic Surgery|2002|289